Recent News

• 03.26.2025 - DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.19.2025 - DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
• 02.04.2025 - DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 01.28.2025 - DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
• 01.28.2025 - DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
• 11.25.2024 - DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

Recent Filings

• 03.26.2025 - 8-K Current report
• 03.26.2025 - EX-99.1 EX-99.1
• 02.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.21.2025 - 8-K Current report
• 01.28.2025 - 8-K Current report
• 01.28.2025 - EX-99.1 EX-99.1
• 01.10.2025 - 8-K Current report
• 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.29.2024 - 8-K/A Current report
• 11.25.2024 - 8-K Current report